Advancing Pain Relief for Cancer Patients Suffering from Oral Mucositis
Stockholm, Sweden – OncoZenge AB appoints LINK Medical, a leading Nordic-based Contract Research Organization (CRO), to execute the pivotal Phase III clinical study of BupiZenge™, the company’s novel lozenge formulation of bupivacaine, designed to relieve oral pain from mucositis in cancer patients.
Study Overview
The Phase III trial will enroll approximately 150 patients across 10–12 sites in Norway, Sweden, Denmark, and Germany, with recruitment and primary results expected in 2026. The study aims to demonstrate superior pain reduction with BupiZenge™ compared to lidocaine, while also assessing improvements in quality of life — including eating ability and sleep — as well as oral intake measured by weight, and the potential to reduce opioid use.
“Oncology and pain management are key focus areas for LINK Medical, a passion we share with the team at OncoZenge and our network of experienced sites across Northern Europe. We are proud to leverage this dedication to help advance the BupiZenge™ clinical program and bring hope to patients affected by oral mucositis worldwide,” says Anders Göransson, CEO of LINK Medical.
About LINK Medical
LINK Medical is a full-service CRO operating in Northern Europe, specializing in pivotal registration clinical trials across multiple countries. With offices in six countries and over 160 dedicated professionals, LINK Medical is committed to high-quality clinical research. For more information, please visit www.linkmedical.eu.
About OncoZenge AB
OncoZenge is a clinical-stage pharmaceutical company focused on developing safe, effective treatments to relieve pain in contexts where current therapies fail—such as cancer therapy–induced oral mucositis. Its lead product, BupiZenge™, is a novel treatment formulation intended to deliver local relief with minimal systemic exposure. OncoZenge is headquartered in Stockholm, Sweden, and is publicly traded under the ticker ONCOZ. For more information, please visit www.oncozenge.se.
